Wondering how viable this organization is. I recently took a position via inVentiv. There was discussion of POTENTIAL for future opportunities with company as an FTE. Now I see they did a 10:1 stock spilt inversion last week because there was a chance that they would be delisted. How viable is this company?
do your homework. Read these articles http://seekingalpha.com/symbol/OREX Contrave and competitive products, Belviq and Qysimia, never reached their potential relatively small weight loss and many side effects. Company has to conduct $260 million in post approval studies for FDA and European FDA with only about 200 million in bank. How much does it cost to promote and support 150 person sales force? Takeda spent $500 million promoting Contrave and annual sales were 51 million. This company will be bankrupt in 2 years.
